Form 4: PTC Therapeutics CFO Pierre Gravier Reports Acquisition of Stock and Stock Options
SEC Form 4
Pierre Gravier, CFO of PTC Therapeutics, reports the acquisition of 22,500 shares of common stock and options to purchase 56,250 shares.
Summary
- On January 3, 2025, Pierre Gravier, the Chief Financial Officer of PTC Therapeutics, acquired 22,500 shares of common stock as restricted stock units.
- These restricted stock units vest in four equal installments annually, starting on January 3, 2026.
- Gravier also acquired options to purchase 56,250 shares of common stock at an exercise price of $46.54.
- These options vest over four years, beginning January 3, 2026, with subsequent vesting every three months.
- Following these transactions, Gravier directly owns 76,771 shares of PTC Therapeutics common stock.
- This includes shares acquired under the company's employee stock purchase plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option grants, which is neither particularly positive nor negative.
Positives
- The acquisition of stock and stock options by a key executive may signal confidence in the company's future performance.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules for the stock and options suggest a multi-year commitment from the executive.
Industry Context
This filing is a routine disclosure related to executive compensation and ownership in a publicly traded company. It's common for executives to receive stock options and restricted stock units as part of their compensation packages.
Comparison to Industry Standards
- Stock option and restricted stock grants are a standard component of executive compensation packages in the biotechnology industry, often used to align management's interests with those of shareholders.
- Vesting schedules of four years are typical, encouraging long-term commitment.
- Companies like BioMarin, Sarepta Therapeutics, and Vertex Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as it indicates the CFO's increased stake in the company's success.
- Employees may view the equity grants as a positive sign of company stability and growth potential.
Key Dates
| Date | Description |
|---|---|
| June 30, 2024 | End of period for employee stock purchase plan, where 339 shares were acquired. |
| December 31, 2024 | End of period for employee stock purchase plan, where 401 shares were acquired. |
| 01/03/2025 | Date of transaction: Acquisition of restricted stock units and stock options. |
| 01/03/2026 | First vesting date for both restricted stock units and stock options. |
| 04/03/2026 | First three-month vesting period for stock options. |
| 01/02/2035 | Expiration date for the stock options. |
| 01/07/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.